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The canonical Wnt signaling pathway, mediated by
the transcription factor b-catenin, plays critical roles
in embryonic development and represents an impor-
tant therapeutic target. In a zebrafish-based in vivo
screen for small molecules that specifically perturb
embryonic dorsoventral patterning, we discovered
a compound named windorphen that selectively
blocks the Wnt signal required for ventral develop-
ment. Windorphen exhibits remarkable specificity
toward b-catenin-1 function, indicating that the two
b-catenin isoforms found in zebrafish are not func-
tionally redundant. We show that windorphen is a
selective inhibitor of p300 histone acetyltransferase,
a coactivator that associates with b-catenin. Finally,
windorphen robustly and selectively kills cancer cells
that harbor Wnt-activating mutations, supporting the
therapeutic potential of this Wnt inhibitor class.INTRODUCTION
Canonical Wnt/b-catenin signaling plays critical roles in embryo-
genesis and adult tissue homeostasis (Clevers, 2006). In the
absence of Wnt ligands, cytoplasmic b-catenin is phosphory-
lated and targeted for proteolytic degradation by the destruction
complex Axin/GSK-3/adenomatous polyposis coli (APC). In the
presence of Wnt ligands, this complex is disassembled, and
stabilized b-catenin translocates to the nucleus to promote
expression of specific Wnt target genes. Because aberrant
Wnt signal activation is thought to cause a number of human
diseases, especially cancers (Malekar et al., 2010; Moon et al.,
2004; Reya and Clevers, 2005; Thorne et al., 2010), small mole-
cules that selectively inhibit Wnt/b-catenin signaling are highly898 Cell Reports 4, 898–904, September 12, 2013 ª2013 The Authorsought after as potential therapeutic leads (Chen et al., 2009;
Emami et al., 2004; Huang et al., 2009; Thorne et al., 2010).
In zebrafish, canonical Wnt signaling is mediated by two
distinct b-catenin isoforms: b-catenin-1, which is highly similar
to mammalian and Xenopus b-catenin; and b-catenin-2, which
is more divergent from others (Figure S4) (Bellipanni et al.,
2006). Although the two b-catenins are highly conserved, with
96.1% sequence identity at the N terminal and the armadillo
repeat domains, the greatest divergence is found within the
87-amino acid C-terminal transactivation domain, with 66.7%
sequence identity. Despite similarities in the sequences and
the expression patterns, only maternally contributed b-catenin-2
is required for dorsal organizer formation, a region equivalent to
the Spemann-Mangold organizer in Xenopus (Bellipanni et al.,
2006), indicating that the two b-catenin isoforms are not func-
tionally redundant. Moreover, after formation of the dorsal
organizer, zygotic contributions of b-catenin-1 are thought to
promote ventral and posterior cell fates (Bellipanni et al., 2006;
Varga et al., 2007). In summary, molecular genetic studies
indicate that, in zebrafish, Wnt/b-catenin-2 signaling early in
embryogenesis is required for dorsal developmental programs;
whereas later, Wnt/b-catenin-1 signaling has the opposite effect
of promoting ventral development.
RESULTS
Discovery of Windorphen, a Small Molecule Wnt
Inhibitor, in a Phenotype-Based Screen
Given the critical roles of Wnt/b-catenin signaling in embryonic
dorsoventral patterning, we devised a chemical screen to
discover selective small molecule Wnt pathway modulators
based on their ability to perturb dorsoventral patterning in zebra-
fish embryos. Briefly, fertilized zebrafish embryos were arrayed
into 96-well microtiter plates, exposed at 3–4 hr postfertilization
(hpf) to compound library, and then visually assessed for pertur-






























WD(µM)   
+ + + + + +-
0 0.50 1 5 10 20
F Untreated WD
Figure 1. WD, which Dorsalizes Zebrafish
Embryo, Inhibits Canonical Wnt Signaling
(A) Chemical structure of WD, (Z) 3-chloro-2,3-
bis(4-methoxyphenyl)acrylaldehyde, is shown.
(B) WD dorsalizes zebrafish embryos. (i) Vehicle-
treated WT zebrafish embryo at 48 hpf. (ii and iii)
Dorsalized embryos treated with 10 mM WD.
(i) Mildly dorsalized embryo is characterized by
loss of ventral tail fin (arrow), whereas (ii) severely
dorsalized embryo is characterized by severely
shortened tail.
(C) In situ hybridization of six-somite-stage (12 hpf)
embryos was performed to evaluate expression of
the dorsal markers Pax2.1, which marks the
midhindbrain boundary, and Krox20, which marks
rhombomeres 3 and 5. In comparison to untreated
embryos (left), Pax2.1 and Krox20 expression are
dramatically expanded in WD-treated embryos
(right). Dorsal view, anterior is to the left.
(D) Time window for dorsalization byWD (20 mM) is
between 4 and 6 hpf. Numbers shown on right are
percentage (%) of embryos dorsalized (dors) upon
various WD treatment schemes. Left end of each
bar or arrow represents the time when WD
treatment was initiated, and the right end of each
bar represents the time when WD was washed out
(n > 100 embryos for each condition).
(E) WD inhibited Wnt3-induced signaling in
b-catenin-responsive TOPFLASH reporter assay
(n = 4; results are represented as mean RLU
[relative luciferase units] ± SE).
(F) In situ hybridization for GFP expression in
Wnt-dependent TOPFLASH-GFP transgenic
zebrafish reveals that WD selectively abrogated
Wnt signaling in the ventral and lateral regions
(arrow) of the 50%epiboly stage (5.3 hpf) embryos,
but not within the dorsal organizer (arrowhead).
Ventral side is to the left.
See also Figures S1, S2, and S3.Procedures). This screen of 30,000 compounds discovered nine
structurally independent hits. One of the hits, subsequently
named windorphen (Wnt inhibitor dorsalizing; WD; Figure 1A),
reproducibly dorsalized zebrafish embryos (Figure 1B). WD
treatment induced marked expansion of the dorsal markers
pax2.1, which demarcates the midhindbrain boundary, and
krox20, amarker of rhombomeres 3 and 5 at the six-somite stage
(Figure 1C). In contrast to our previously identified BMP inhibitor
dorsomorphin, which dorsalized embryos when administered
over a wide developmental time window (<1–8 hpf) (Yu et al.,
2008), the temporal window for WD action was very narrow,
between 4 and 6 hpf, corresponding to the early epiboly stage
(Figure 1D). Moreover, in contrast to dorsomorphin, WD had no
effect either on BMP-responsive luciferase reporter assay or
on BMP4-induced phospho-SMAD1/SMAD5/SMAD8 activa-
tion, suggesting that WD-induced dorsalization did not involve
BMP signal inhibition (Figures S1A and S1B).
In canonical Wnt/b-catenin reporter cell line STF293 (Thorne
et al., 2010; Xu et al., 2004), WD inhibited Wnt3a-inducible
TOPFLASH-luciferase activity in a dose-dependent manner
with a calculated IC50 of about 1.5 mM (Figure 1E). By contrast,
BAS, a structural analog of WD, neither dorsalized embryos
nor inhibited Wnt reporter activity (Figures S1E and S1F).CelAdditionally, WD did not affect either Hedgehog or TNF-a/
NF-kB reporter activity (Figures S1C and S1D), indicating that
it selectively targeted Wnt signaling. Thus, WD perturbs dorso-
ventral patterning through selective inhibition of canonical Wnt
signaling. Interestingly, there was considerable batch-to-batch
variability in WD’s ability to both dorsalize embryos and inhibit
Wnt signaling. Mass spectroscopic and nuclear magnetic reso-
nance analyses of active and inactive WD batches revealed
that the active batches were distinguishable by the presence
of the Z isoform of WD that comprises a minor (13%) constitu-
ent not present in the inactive batches (Figures S2 and S3). In all
subsequent studies, only the batches capable of dorsalizing
embryos were used, including potency determinations. Thus,
the z isomer of WD perturbs dorsoventral patterning through
selective inhibition of canonical Wnt signaling.
WD Selectively Targets Some, but Not All, Wnt Signals
in Zebrafish Embryos
That WD is a Wnt inhibitor came as a surprise because such a
compound was predicted to ventralize the embryo by blocking
the formation of the dorsal organizer (Kelly et al., 2000; Pelegri
and Maischein, 1998; Schier and Talbot, 2005). WD, however,





Figure 2. WD Blocks Wnt Signaling Down-
stream of b-Catenin Destruction Complex
(A) WD inhibited Wnt signaling induced by
BIO in TOPFLASH-luciferase assays in STF293
cells (n = 4; results are represented as mean
RLU ± SE).
(B) WD (20 mM) rescued the loss of telencephalon
and eyes in mbl mutant zebrafish with defective
Axin1 gene. Top view shows untreated Axin1/
mbl mutant zebrafish embryo (3 days old).
Bottom view presents WD-treated embryo with
normal/restored eyes and telencephalon. Quanti-
fication of telencephalon/eye loss phenotype in
mbl mutants and BIO-treated embryos, following
treatment with WD or DMSO control, is shown.
p value was determined using Student’s two-tailed
t test.
(C) Model illustrates TOPFLASH-luciferase assay,
with components of the Wnt/b-catenin signaling
and various means to perturb them. Briefly,
disruption of the b-catenin degradation com-
plex, either through pharmacological inhibition
of GSK3b using the small molecule BIO or a
genetic mutation in Axin (mlb), results in nuclear
b-catenin accumulation and subsequent Wnt
reporter activation.
(D) WD treatment does not block Wnt3a-induced
b-catenin nuclear translocation in RKO cells. RKO
cells were immunostained for b-catenin (red) and
counterstained with DAPI (blue) following 24 hr
incubation without Wnt3a, with Wnt3a, and with
Wnt3a plus WD (20 mM).
(E) WD inhibited Wnt signaling induced by
overexpression of the constitutively active human
b-catenin (cat) mutant (S33Y) in TOPFLASH-
luciferase assay (n = 4; results are represented as
mean RLU ± SE).
(F) WD blocked Wnt signaling induced by
overexpression of the zebrafish b-catenin-1 in
TOPFLASH-luciferase assay in STF293 cells
(n = 3).
(G) WD did not block Wnt signaling induced by
overexpression of the zebrafish b-catenin-2 (n = 3)
in STF293 cells.
See also Figure S4.from 4 to 6 hpf (Figure 1D) suggested that it disrupted a
patterning process subsequent to the formation of organizer.
Indeed, using TOPFLASH-GFP transgenic zebrafish embryos,
in which a Wnt/b-catenin-responsive promoter drives the GFP
expression (Dorsky et al., 2002), we found that WD treatment
selectively abrogated Wnt signaling in ventral and lateral regions
of the 50% epiboly stage embryo (5.3 hpf), but not the Wnt
signaling within the dorsal organizer (Figure 1F). These results
suggest that WD selectively targets some, but not all, aspects
of Wnt/b-catenin signaling involved in dorsoventral patterning.
WD Targets a Component Downstream of Both the
b-Catenin Destruction Complex and b-Catenin Nuclear
Translocation
To definewhereWDacts in the canonicalWnt signaling pathway,
we utilized BIO, a selective GSK3 inhibitor that induces Wnt900 Cell Reports 4, 898–904, September 12, 2013 ª2013 The Authorsignaling by blocking b-catenin phosphorylation and subsequent
degradation (Sato et al., 2004). In STF293 reporter cells, addition
of BIO alone robustly induced b-catenin-dependent luciferase
activity, and this BIO-induced reporter activity was blocked by
WD in a dose-dependent manner (Figures 2A and 2C; Table
S1). We sought corroborating in vivo evidence by using homozy-
gous recessive masterblind (mbl; Axin1tm213) mutant zebrafish,
which carry the L399Q mutation in the axin1 gene (Heisenberg
et al., 2001; van deWater et al., 2001). Inmblmutants, a defective
Axin1/b-catenin destruction complex leads to aberrant activation
ofWnt signaling and the resultant loss of telencephalon and eyes
(Figures 2B and 2C). Similar phenotype is also seen in embryos
treated at 6 hpf with BIO. In both mbl mutants and BIO-treated
embryos, WD exposure reproducibly rescued the telenceph-
alon/eye phenotype (Figure 2B). Next, in human colon carcinoma
RKO cells, we found that WD had no effect on Wnt3a-induceds
translocation of b-catenin to the nucleus (Figure 2D). Taken
together, these results indicate that WD selectively targets a
signaling component in the Wnt pathway that lies downstream
of both b-catenin destruction complex and b-catenin nuclear
translocation. Indeed, WD abrogated TOPFLASH-luciferase
induction in STF293 cells expressing the constitutively active
human b-catenin mutant (S33Y), which is resistant to GSK3-
mediated degradation (Figure 2E) (Morin et al., 1997).
WD Selectively Targets the Function of b-Catenin-1, but
Not b-Catenin-2
Importantly, WD blocked reporter induction in STF293 cells
overexpressing the zebrafish b-catenin-1 (Figure 2F), but not
the zebrafish b-catenin-2 (Figure 2G), indicating that WD selec-
tively targets the function of the zebrafish b-catenin-1 and the
closely related mammalian homologs, but not the more diver-
gent zebrafish b-catenin-2 (Figure S4). Together with the fact
that WD treatment causes just dorsalization of the embryonic
axis and disrupts Wnt signaling only in ventral and lateral regions
of the epiboly stage embryo (Figure 1F), these results support the
notion that the two zebrafish b-catenin isoforms are not func-
tionally equivalent.
WDFunctionally Targets theC-Terminal Transactivation
Domain of b-Catenin-1, Disrupting Its Association with
p300
Because b-catenin-2 is most divergent from the mammalian
b-catenin at the C-terminal transactivation domain (Figure S4),
we examined whether WD targets the mammalian b-catenin
via this domain. We used an expression construct in which the
fusion protein LEFDN-bCTA (or LF-TA in Figure 3A; Table S1)
comprised of the TCF/LEF1 DNA-binding domain fused to the
C-terminal transactivation domain (amino acids 695–781) of
mouse b-catenin (Vleminckx et al., 1999). As previously demon-
strated, the LEFDN-bCTA fusion protein was able to induceWnt/
b-catenin reporter expression. Importantly, WD blocked reporter
induction by LEFDN-bCTA in a dose-dependent manner (Fig-
ure 3A). However, WD did not block reporter induction by the
LEFDN-VP16 (or LF-VP in Figure 3B) fusion protein comprised
of LEF1 DNA-binding domain and the transactivation domain
of the herpes simplex virus VP16 protein (Figure 3B; Table S1),
suggesting that inhibitory effects of WD were specific to the
C-terminal transactivation domain of b-catenin-1 (Figure 3C;
Table S1).
The closely related, yet nonredundant, histone acetyltrans-
ferases (HATs) CREB-binding protein (CBP) and p300 are
known to associate with the C-terminal transactivation domain
of b-catenin to mediate its transactivation activity (Hecht et al.,
2000; Ma et al., 2005). To determine whether WD disrupted
interaction of b-catenin with CBP or p300, we incubated cell
lysates with the tested compounds and performed coimmuno-
precipitation experiments. In human colon adenocarcinoma cell
line SW480, endogenous CBP was readily coimmunoprecipi-
tated with b-catenin in the presence of inactive analog BAS,
or 30 mM WD (Figure 3D). In contrast, ICG-001, a Wnt inhibitor,
specifically disrupted b-catenin and CBP interaction as
previously reported (Figure 3D) (Emami et al., 2004). The
b-catenin:p300 coimmunoprecipitation experiments were con-Celducted in HEK293 cells following transfection with a HA-tagged
p300 construct, as previously performed by Emami et al.
(2004), because endogenous p300 was expressed at relatively
low levels in SW480 cells, resulting in inconsistent results. In
HEK293 cells overexpressing the HA-tagged p300, the physical
association of b-catenin with p300 was disrupted by WD, but
not BAS (Figure 3E). In addition, WD did not disrupt the inter-
action of b-catenin with its DNA-binding partner LEF1/TCF4
in HEK293 cells treated with Wnt3a (Figure S5). These
results suggest that WD inhibits Wnt signaling by selectively
targeting the association of b-catenin with p300, but not CBP
or LEF1/TCF4.
WD Directly and Selectively Targets the p300 HAT
Next, we examined whether WD directly targets p300, specif-
ically its HAT activity. In in vitro acetyltransferase assays using
purified human HATs p300, CBP, GCN5, KAT5, MYST2/KAT7,
MYST4/KAT6B, and P300/CBP-associated factor (PCAF), WD,
but not BAS, inhibited the p300 HAT activity with an IC50 (con-
centration causing 50% inhibition) of 4.2 mM. In contrast, WD’s
IC50 values toward other HATs, including CBP, were approxi-
mately 10-fold higher; much higher than the concentrations
used to disrupt Wnt signaling in embryos and in cultured cells
(Figure 3F). WD’s selective effects on p300 versus CBP
support the growing evidence that p300 and CBP, whereas
traditionally considered to be functionally interchangeable,
are functionally nonredundant (Emami et al., 2004; Ma et al.,
2005; Ramos et al., 2010; Teo and Kahn, 2010). Indeed, we
found that siRNA knockdown of either p300 or CBP led to a
significant decrease in Wnt reporter activity, versus scrambled
siRNA (Figure S6). Taken together, our study indicates that
WD blocks Wnt signaling by selectively targeting p300, dis-
rupting its association of the C-terminal transactivation domain
of b-catenin-1.
WD Robustly Induces Apoptosis in Wnt-Dependent
Tumor Cells
Canonical Wnt/b-catenin signaling has been strongly linked to
the development of numerous malignancies, particularly gastro-
intestinal cancers of which 90% are thought to involve aberrant
Wnt signal activation (Clevers, 2006; Moon et al., 2004; Reya
and Clevers, 2005). To query the therapeutic potential of
chemical inhibition of b-catenin, we evaluated WD’s effects on
the viability of cancer cells. In human colon adenocarcinoma
SW480 cells, in which Wnt signaling is constitutively activated
due to defective APC gene, WD (20 mM) caused widespread
apoptosis after 72 hr of treatment (Figure 3G). In addition, in
cell viability assays in the presence of increasing concentrations
of WD for 72 hr, human carcinoma cell lines noted to have acti-
vation of Wnt signaling, such as human colon cancer cell lines
SW480 and RKO and prostate cancer cell lines DU145 and
PC3 (Lu et al., 2009; Morin et al., 1997; Suzuki et al., 2008), ex-
hibited sensitivities to WD (IC50 values of 15.0, 19.2, 21.8, and
19.0 mM, respectively; Figure 3H). In contrast, WD did not display
cytotoxic activity toward the human lung cancer cell line H460,
which does not exhibit aberrant Wnt signal activation and is
insensitive to b-catenin depletion or to the small molecule Wnt







Figure 3. WD Targets the C-Terminal Transactivation Domain of b-Catenin-1, Disrupts Its Interaction with Coactivators CBP/p300, and Kills
Human Carcinoma Cell Lines
(A) WD blocked Wnt signaling induced by overexpression of the LEFDN-bCTA (LEF-TA) fusion protein comprised of the LEF1 DNA-binding domain and the
b-catenin C-terminal transactivation domain in a dose-dependent manner.
(B) WD did not block Wnt signaling induced by overexpression of the LEFDN-bCTA (LEF-VP) fusion protein comprised of the LEF1 DNA-binding domain and the
transactivation domain of the herpes simplex virus VP16 protein.
(legend continued on next page)
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observations raise the possibility that selective b-catenin inhibi-
tors like WD may be attractive lead compounds for the develop-
ment of Wnt pathway-targeted cancer therapeutics.
DISCUSSION
Here, we report the identification of a small-molecule Wnt/
b-catenin signal inhibitor, named WD, in a large-scale in vivo
chemical genetic screen. WD dorsalizes zebrafish embryos
when administered during epiboly and rescues the loss of
telencephalon caused by overactivation of Wnt signaling in
GSK3-inhibited and axin1 mutant embryos. Moreover, we pro-
vide evidence that WD specifically targets the function of the
C-terminal transactivation domain of b-catenin-1, but not
b-catenin-2. Among cofactors that interact with the C-terminal
transactivation domain of b-catenin, WD directly and selectively
targets p300, disrupting the association of the mammalian
b-catenin with p300, but not CBP. Although p300 and CBP are
highly homologous and often considered to be interchangeable,
growing evidence suggests divergent roles of p300 andCBP (Ma
et al., 2005; Ramos et al., 2010; Teo and Kahn, 2010). Indeed,
small-molecule ICG-001 can selectively disrupt interaction
between b-catenin and CBP but not b-catenin and p300 (Emami
et al., 2004), consistent with our observation that, despite their
close structural similarities, it is possible to develop small
molecules that can discriminate between CBP and p300.
Our findings support earlier studies indicating that the two
zebrafish b-catenin isoforms play nonredundant roles in embry-
onic dorsoventral patterning, with b-catenin-2 required for the
formation of the dorsal organizer and b-catenin-1 involved
primarily in the ventral development. However, how the devel-
oping embryo can differentiate between these two isoforms
when their transcripts are present ubiquitously is unknown
(Bellipanni et al., 2006). Our results suggest a potential mecha-
nism in which the two b-catenin isoforms interact with distinct
binding partners that initiate the divergent developmental
programs. Moreover, our results indicate that the b-catenin-
1:p300 interaction is specifically required for ventral develop-
ment of the zebrafish embryo. Finally, we show that WD can
selectively kill cancer cells in which Wnt signaling is known to
be aberrantly activated. Because overexpression of p300, but
not CBP, is associated with poor prognosis in human colon
cancers, drugs that selectively target the b-catenin:p300 inter-
action like WD may have a therapeutic advantage as antineo-
plastic agents (Ishihama et al., 2007). In summary, our unbiased,
in vivo chemical genetic approach demonstrates the feasibility of(C) Model illustratesWD targeting the function of the C-terminal transactivation do
reporter gene (TOP-luciferase) via its association with TCF/LEF1 (LEF).
(D) Western blot showing coimmunoprecipitation of endogenous CBP and b-cate
30 mM) of WD, inactive analog BAS, and 10 mM ICG-001.
(E) Western blot showing coimmunoprecipitation of transfected HA-tagged p3
centrations (5 and 30 mM) of BAS and WD.
(F) Inhibitory effects of WD and BAS on seven human HATs in in vitro assays. W
(G) TUNEL apoptosis assay in human colon adenocarcinoma SW480 cells follow
TUNEL signal is colored green, DAPI counterstain is blue, and yellow is merged.
(H) Percentage of viable human cancer cells (SW480, RKO, DU145, PC3, and H46
concentrations of WD (n = 4 for each data point).
For (A)–(C), n = 4 each. Results are represented as mean RLU ± SE. See also Fig
Celdeveloping remarkably selective inhibitors of a nontraditional
therapeutic target.
EXPERIMENTAL PROCEDURES
All zebrafish experiments were approved by Vanderbilt University Institutional
Animal Care and Use Committee.
Chemical Screen
Chemical screen for small molecules that perturb dorsoventral axis was
performed as previously described (Hao et al., 2010a; Hong, 2009; Yu et al.,
2008) and are detailed in the Supplemental Information.
Compound Synthesis
Methods for synthesis of WD and BAS are detailed in the Supplemental
Information and the synthesis schemes represented in Figure S7.
Luciferase Reporter Assays
For Wnt/b-catenin signaling assay, STF293 cells (HEK293 cells stably trans-
fected with TOPFLASH [TCF/LEF1-optimized promoter]-firefly luciferase
reporter) (Thorne et al., 2010) were seeded in 96-well plates and incubated
overnight with the various concentrations of the compound in the presence
of Wnt3a-conditioned media (made according to directions in the American
Type Culture Collection website). The cell-based assays for BMP signaling,
Hedgehog signaling, and TNF-a signaling are detailed in the Supplemental
Information.
Coimmunoprecipitation
Cells were lysed in M-PER lysis buffer (Thermo Scientific) supplemented with
Complete Mini Protease Inhibitor Cocktail (Roche). Cell lysate was incubated
with the tested compounds for 4 hr, followed by incubation withmouse Active-
b-catenin antibody (Millipore; Clone 8E7, 1:50 dilution) at 4C overnight.
Antibody-antigen complex was conjugated to Protein A agarose beads
(Thermo Scientific) for 2 hr at 4C, followed by at least three cold TBS washes.
The beads were spun down, and bound protein was eluted in LDS buffer
(Invitrogen). Eluted protein was resolved in SDS-PAGE and transferred onto
nitrocellulose membrane for western blotting.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2013.07.047.
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